An interventional study of Placebo and experimenmtal in BMI, Fasting Blood Glucose and HbA1c, sponsored by University of Lahore. Not yet recruiting at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Lahore · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan — 28 open to participants now, 35 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Pakistan.
Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, this one is the 41st largest by planned enrollment of the 89 interventional ones that give a count, is one of 16 that started in 2026, is one of 59 with no phase, reaches primary completion later than 27 of the 34 other live ones, and was the 98th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →28 of the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan are open now. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Ages 40–65
Green International University · Sites in Pakistan
Ages 30–65
Ibadat International University, Islamabad · Sites in Pakistan
Ages 50–70
Foundation University Islamabad · Sites in Pakistan
Ages 30–55
Khyber Medical University Peshawar · Sites in Pakistan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 21
First in 2006; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 99 across the 89 interventional studies, 1,031 across the 9 observational. Of the 56 that completed or were terminated, 5 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 98 have an industry lead sponsor. The 10 most frequent:
University of Lahore is the lead sponsor of 237 studies on the registry; 47 are open to participants now.
University of Lahore has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetes Mellitus, Type 2 with a site in Pakistan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073768Phase 3Khyber Medical College, PeshawarComparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients | 2026-12-26 |
| NCT06570057Baqai Institute of Diabetology and EndocrinologyFeasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors | 2026-11 |
| NCT06561126Khyber Medical University PeshawarEngagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D] | 2026-11-30 |
| NCT07814742National University of Medical Sciences, PakistanEffectiveness of UrDiaCare | 2026-12-31 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 10-week randomized controlled trial evaluated the nutritional quality and dose-specific effects of foxtail millet muffins (50 and 100 g/day) alongside a low-glycemic index diet among 102 obese adults with T2DM. The study will assess changes in glycemic control, lipid profile, liver function, and anthropometric parameters to investigate the potential of foxtail millet as a functional dietary intervention for diabetes management.
This 10-week randomized controlled trial investigated the nutritional quality and potential health benefits of foxtail millet (Setaria italica) muffins among 102 obese adults with type 2 diabetes mellitus (T2DM). Participants were randomly allocated into three groups: placebo (wheat muffin, T₀), low-dose foxtail millet muffin (50 g/day, T₁), and high-dose foxtail millet muffin (100 g/day, T₂), with all groups following a standardized low-glycemic index diet. The nutritional composition, including proximate constituents and mineral content, and sensory acceptability of the muffins were evaluated using standard AOAC procedures and a 9-point hedonic scale. Anthropometric measurements, including body weight, BMI, and other relevant parameters, were assessed alongside fasting blood glucose (FBG), glycated hemoglobin (HbA1c), lipid profile, and liver function biomarkers at baseline and after the intervention. The study aimed to determine whether daily consumption of foxtail millet-based muffins could provide a nutritionally valuable dietary option and support improvements in glycemic regulation, metabolic health, and anthropometric status among obese adults with T2DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T₀; wheat muffin
Dietary Supplement: Placebo
low-dose foxtail millet muffin (T₁; 50 g/day)
Dietary Supplement: experimenmtal
high-dose foxtail millet muffin (T₁; 100 g/day)
Dietary Supplement: high-dose foxtail millet muffin
wheat muffin
low-dose foxtail millet muffin (T₁; 50 g/day)
high-dose foxtail millet muffin (T₂; 100 g/day)
bmi
Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m²) and expressed in kg/m².
Time frame: 10 weeks
HBA1c
Glycated hemoglobin (HbA1c) was measured to assess average blood glucose levels over the preceding 2-3 months and expressed as a percentage (%).
Time frame: 10 weeks
LIPID PROFILE
Lipid profile, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), was assessed and expressed in mg/dL.
Time frame: 10 WEEKS
Plan to share: No
Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.
Of 2,072 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.
Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.